Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Industry's Rebate Arms Race: Securing Market Access At A Cost

This article was originally published in Scrip

Executive Summary

Rebates have become industry's go-to for securing market access for drugs in competitive therapeutic areas in the US. But as payers push back, competitive rebating is intensifying and eating into the bottom line.


Related Content

Pharma's Middlemen Get Fatter: PBM, Health Plan Rebates Near $58bn
The Outcomes-Based Reimbursement Experiment
Pfizer’s Read Criticizes Rebates Amid Changing Market Dynamics
Oncology Is Booming But Cost Outlook Is Grim, IMS Says
Amgen's Harper Says Repatha Is Priced Right